Clinical Trial Update: A Study to Learn About the Study Medicine Sisunatovir in Adults With Respiratory Syncytial Virus (RSV) Infection [Phase 2, Phase 3]

View source ↗

Summary

Pfizer's Phase 2/3 study of sisunatovir in adults with Respiratory Syncytial Virus infection was terminated and results were posted in 2025.

Upgrade for the full analysis, importance score, and drug timeline.

Diseases / indications

• Respiratory Syncytial Virus Infection

Drugs mentioned

• Sisunatovir (Sisunatovir)

Snippet

Sponsor: Pfizer | Conditions: Respiratory Syncytial Virus Infection | Phase 2, Phase 3 | Status: TERMINATED | Results posted: 2025-11-10